Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 11c vs. 12c a year ago

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Fourth quarter net sales were flat at $119.0 million and comparable sales increased 1% Fourth quarter GAAP loss per share was $3.97 Fourth quarter adjusted loss per share was $0.31 (see No.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Fiscal Year 2020 - Total company non-GAAP revenue of $.....»»

Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update.....»»

Adjusted EBITDA reaches $4.2 million and Net income incre.....»»

Potential Vaccine, TNX-1800 in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company's Ho.....»»

Seclidemstat Achieves Dose-Escalation Milestone in Phase 1/2 Ewing Sarcoma Clinical Trial Sixth Level Dosing Cohort Now Proceeding; On Track To Report Topline Data in 2020 HOUSTON, March 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.....»»

Reports Q4 GAAP Earnings per Diluted Share of $1.61 versus $0.74 in Q4 2018 Reports Q4 Adjusted Earnings per Diluted Share of $1.85 versus $1.10 in Q4 2018 Defers Fiscal .....»»

REDWOOD CITY, Calif......»»

-- Streamlined URIROX-2 Design Potentially Reduces Target Length and Cost of Trial -- -- Regulatory Engagement on Regi.....»»

- New Drug Application for VP-102 for the treatment of molluscum contagiosum was accepted for filing by the U.S. Food and Drug Adm.....»»

Quarterly GAAP Revenue Totaled Record $35.1M, Up 17% Year-over-Year on a.....»»

Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2020 Raised $65 million in gross proceeds from privat.....»»

Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019.....»»

XERMELO® (telotristat ethyl) 2019 U.S. Net Sales Reached $31.0 Million THE WOODLANDS, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three .....»»

- Key Recent Clinical Milestones.....»»

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development a.....»»

– Topline data from Phase 3 NODE-301 trial of etripamil in pati.....»»